Cargando…

Metabolomics Reveals Process of Allergic Rhinitis Patients with Single- and Double-Species Mite Subcutaneous Immunotherapy

Allergen immunotherapy (AIT) is the only treatment that can change the course of allergic diseases. However, there has not been any research on metabolic reactions in relation to AIT with single or mixed allergens. In this study, patients with allergic rhinitis caused by Dermatophagoides pteronyssin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Peiyan, Yan, Guanyu, Zhang, Yida, Huang, Huimin, Luo, Wenting, Xue, Mingshan, Li, Na, Wu, Jian-Lin, Sun, Baoqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471092/ https://www.ncbi.nlm.nih.gov/pubmed/34564431 http://dx.doi.org/10.3390/metabo11090613

Ejemplares similares

Dropouts From Sublingual Immunotherapy and the Transition to Subcutaneous Immunotherapy in House Dust Mite-Sensitized Allergic Rhinitis Patients
por: Chen, Huan, et al.
Publicado: (2022)

Immunologic changes after house dust mite modified rush subcutaneous immunotherapy in allergic rhinitis children
por: Rattanamanee, Tipyapa, et al.
Publicado: (2022)

Subcutaneous Immunotherapy Improves the Symptomatology of Allergic Rhinitis
por: Lourenço, Edmir Américo, et al.
Publicado: (2015)

Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world
por: Ciprandi, Giorgio, et al.
Publicado: (2017)

A Retrospective Study of Clinical Response Predictors in Subcutaneous Allergen Immunotherapy With House Dust Mites for Allergic Rhinitis
por: Lee, Ji-Ho, et al.
Publicado: (2018)

Safety of specific subcutaneous immunotherapy in patients with allergic rhinitis
por: Da Fonseca, Mario Henrique Almeida, et al.
Publicado: (2015)

Efficacy and Safety of Subcutaneous Allergen Immunotherapy for Allergic Rhinitis
por: Sohn, Myung Hyun
Publicado: (2018)

Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial
por: Bożek, Andrzej, et al.
Publicado: (2017)

Analysis of Peanut Allergen Components Sensitization and Cross Reaction with Pollen Allergen in Chinese Southerners with Allergic Rhinitis and/or Asthma
por: Luo, Wenting, et al.
Publicado: (2021)

Clinical Efficacy Evaluation of 1-Year Subcutaneous Immunotherapy for Artemisia sieversiana Pollen Allergic Rhinitis by Serum Metabolomics
por: Shi, Hai-Yun, et al.
Publicado: (2020)

Precision Medicine in Mite Allergic Rhinitis
por: González-Pérez, Ruperto, et al.
Publicado: (2021)

Outcome of Sublingual Immunotherapy in Patients With Allergic Rhinitis Sensitive to House Dust Mites
por: Kim, Seon-Tae
Publicado: (2015)

Administration and burden of subcutaneous immunotherapy for allergic rhinitis in clinical practice in Canada
por: Blume, Steven W, et al.
Publicado: (2014)

Subcutaneous allergen immunotherapy with dermatophagoides pteronyssinus in patient with local allergic rhinitis
por: Rondon, Carmen, et al.
Publicado: (2015)

Safety Profile and Issues of Subcutaneous Immunotherapy in the Treatment of Children with Allergic Rhinitis
por: Endaryanto, Anang, et al.
Publicado: (2022)

Early Compliance and Efficacy of Sublingual Immunotherapy in Patients with Allergic Rhinitis for House Dust Mites
por: Chang, Hyun, et al.
Publicado: (2009)

Mite-Allergic Rhinitis: How to Evaluate Clinical Efficacy in Allergen-Specific Immunotherapy Trials?
por: Pfaar, Oliver, et al.
Publicado: (2015)

Allergen-specific immunotherapy with Alutard SQ improves allergic inflammation in house-dust mites-induced allergic asthma rats through inactivation of the HMGB1/TLR4/NF-κB pathway
por: Zhai, Yingying, et al.
Publicado: (2023)

Identification of Robust Biomarkers for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With House Dust Mite-Induced Allergic Rhinitis by Multiple Cytokine Profiling
por: Xie, Shaobing, et al.
Publicado: (2022)

House dust mite subcutaneous immunotherapy has sustained long‐term effectiveness on allergic rhinitis and asthma: A 10‐year follow‐up
por: Rodriguez‐Plata, Elena, et al.
Publicado: (2023)

Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in U.S. and Canadian Clinical Practice
por: Blume, Steven W., et al.
Publicado: (2015)

Changes in basophil activation during immunotherapy with house dust mite and mugwort in patients with allergic rhinitis
por: Kim, Sae-Hoon, et al.
Publicado: (2018)

Safety of Ultra-rush Schedule of Subcutaneous Allergen Immunotherapy With House Dust Mite Extract Conducted in an Outpatient Clinic in Patients With Atopic Dermatitis and Allergic Rhinitis
por: Lee, So-Hee, et al.
Publicado: (2019)

A single center retrospective study of systemic reactions’ distribution and risk factors to subcutaneous immunotherapy with dust mite extract in patients with allergic rhinitis and/ or asthma
por: Zhang, Xude, et al.
Publicado: (2023)

Role of Predatory Mites in Persistent Nonoccupational Allergic Rhinitis
por: Poza Guedes, Paloma, et al.
Publicado: (2016)

Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases
por: Yang, Yaqi, et al.
Publicado: (2021)

Comparison of Long-term Efficacy of Subcutaneous Immunotherapy in Pediatric and Adult Patients With Allergic Rhinitis
por: Huang, Yanran, et al.
Publicado: (2018)

Subcutaneous immunotherapy induces alterations in monocytes and dendritic cells homeostasis in allergic rhinitis patients
por: Sousa, Letícia, et al.
Publicado: (2018)

Effects of Serum Vitamin D and Efficacy of Subcutaneous Immunotherapy in Adult Patients With Allergic Rhinitis
por: Joudi, Maryam, et al.
Publicado: (2019)

Interactive Network Platform Improves Compliance and Efficacy of Subcutaneous Immunotherapy for Patients with Allergic Rhinitis
por: Shen, Zhiying, et al.
Publicado: (2019)

Efficacy of subcutaneous immunotherapy for patients with asthma and allergic rhinitis in Korea: effect on eosinophilic inflammation
por: Kim, Chang Keun, et al.
Publicado: (2021)

Nasal cytology can predict clinical efficacy of subcutaneous immunotherapy in intermittent allergic rhinitis
por: Jura-Szołtys, Edyta, et al.
Publicado: (2022)

Sublingual immunotherapy in allergic rhinitis
por: Han, Doo Hee, et al.
Publicado: (2011)

Allergic rhinitis behavioral changes after Indonesian house dust mites allergenic extract administration as immunotherapy
por: Pratama, Yusuf Alif, et al.
Publicado: (2023)

Identification of Novel Biomarkers for Evaluating Disease Severity in House-Dust-Mite-Induced Allergic Rhinitis by Serum Metabolomics
por: Xie, Shaobing, et al.
Publicado: (2021)

Sublingual or Subcutaneous immunotherapy for Seasonal Allergic Rhinitis (AR): an indirect analysis of efficacy, safety and cost
por: Dranitsaris, George, et al.
Publicado: (2014)

The early-phase transcriptome and the clinical efficacy analysis in three modes of subcutaneous immunotherapy for allergic rhinitis
por: Huang, Jingyu, et al.
Publicado: (2023)

Can development of asthma and bronchial hyperreactivity be reduced by subcutaneous immunotherapy in adult patients with allergic rhinitis?
por: TEPETAM, Fatma Merve, et al.
Publicado: (2023)

157 The Post-Treatment Efficacy of House Dust Mite Sublingual Allergen Immunotherapy Tablets in Adults With Allergic Rhinitis
por: Bergmann, Karl-Christian, et al.
Publicado: (2012)

Long-term Effects of Specific Allergen Immunotherapy Against House Dust Mites in Polysensitized Patients With Allergic Rhinitis
por: Kim, Sang Hoon, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_99jr2k5f5brcr0b1k7lfjrffas